Dr. Volker Knappertz, MD, DMsc - Heinrich Heine University, Dusseldorf

Dr. Volker Knappertz

MD, DMsc

Heinrich Heine University, Dusseldorf

Potomac, MD, MD | United States

Main Specialties: Neurology

Additional Specialties: Neurology

Dr. Volker Knappertz, MD, DMsc - Heinrich Heine University, Dusseldorf

Dr. Volker Knappertz

MD, DMsc

Introduction

Primary Affiliation: Heinrich Heine University, Dusseldorf - Potomac, MD, MD , United States

Specialties:

Additional Specialties:

Publications

28Publications

593Reads

89Profile Views

232PubMed Central Citations

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.

Prog Neurobiol 2017 05 4;152:114-130. Epub 2016 Mar 4.

Teva Pharmaceutical Industries, Petach Tikva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pneurobio.2016.02.001DOI Listing
May 2017
33 Reads
4 Citations
9.992 Impact Factor

Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.

Expert Opin Drug Saf 2017 Feb;16(2):247-255

e Department of Neurology and INSPE , Vita-Salute San Raffaele University , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2017.1274728DOI Listing
February 2017
6 Reads
1 Citation
2.911 Impact Factor

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.

BMC Neurol 2016 Sep 17;16:176. Epub 2016 Sep 17.

Teva Pharmaceutical Industries, Petach Tikva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12883-016-0702-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027083PMC
September 2016
21 Reads
2.040 Impact Factor

Causes of death among persons with multiple sclerosis.

Mult Scler Relat Disord 2015 Sep 18;4(5):484-490. Epub 2015 Jul 18.

University of Manitoba, Departments of Internal Medicine & Community Health Sciences, Winnipeg, MB, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2015.07.008DOI Listing
September 2015
40 Reads
2 Citations

Challenges and opportunities in designing clinical trials for neuromyelitis optica.

Neurology 2015 Apr 3;84(17):1805-15. Epub 2015 Apr 3.

From the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; MedImmune Ltd. (G.B., A.F.), Riverside Building, Granta Park, Great Abington, Cambridge, UK; Guthy-Jackson Foundation (J.M.B., K.V.H.), San Diego, CA; Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado Denver, Aurora; Novartis Pharmaceuticals Corporation (P.S.C.), East Hanover, NJ; Department of Neurology (B.A.C.C.), University of California San Francisco; CIC (Clinical Investigation Center) INSERM and UMR 1119 (J.d.S.), INSERM, Federation de Medecine Translationelle de Strasbourg, Université de Strasbourg; Department of Multiple Sclerosis Therapeutics (K.F.), Tohoku University, Sendai, Japan; Department of Neurology (B.G.), University of Texas Southwestern; Chugai Pharma USA (S.H., A.T.M.), Berkeley Heights, NJ; PPD Inc. (W.H.), Wilmington, NC; Department of Neurology (O.K.), Wayne State University, Detroit, MI; Teva Pharmaceuticals (V.K.), Frazer, PA; Department of Neurology (V.K.), Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology (M.L.), Johns Hopkins University, Baltimore, MD; Department of Neurology (J.P.), Oxford University Hospital Trust, UK; Department of Ophthalmology and Visual Sciences (T.J.S.), Kellogg Eye Center, and Division of Metabolism, Endocrine, and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; Department of Health Science (M.P.S.), University of Genoa, Italy; David Geffen School of Medicine at UCLA (K.V.H.), Los Angeles, CA; GlaxoSmithKline (S.V.), Research Triangle Park, NC; Center of Neuroimmunology (P.V.), Institute of Biomedical Research August Pi Sunyer (IDIBAPS)-Hospital Clinic Barcelona, Villarroel, Spain; United States Food and Drug Administration (M.K.W.), Center for Drug Evaluation and Research, Silver Spring, MD; Alexion Pharmaceuticals Inc. (W.W.), Cheshire, CT; Department of Neurology (D.M.W.), Mayo Clinic, Scottsdale, AZ; Department of Medicine (M.R.Y.), Divisions of M

View Article

Download full-text PDF

Source
http://www.neurology.org/content/84/17/1805.full.pdf
Web Search
http://www.neurology.org/cgi/doi/10.1212/WNL.000000000000152
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000001520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424131PMC
April 2015
49 Reads
4 Citations
8.290 Impact Factor

Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.

J Neurol 2015 Mar 27;262(3):648-53. Epub 2014 Dec 27.

Department of Neurology, Buffalo Neuroimaging Analysis Center, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, 100 High St., Buffalo, NY, 14203, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-014-7616-0DOI Listing
March 2015
18 Reads
4 Citations
3.380 Impact Factor

CD19 as a molecular target in CNS autoimmunity.

Acta Neuropathol 2014 Aug 4;128(2):177-90. Epub 2014 Jul 4.

Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs00401-014-13
Web Search
http://link.springer.com/10.1007/s00401-014-1313-z
Publisher Site
http://dx.doi.org/10.1007/s00401-014-1313-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296724PMC
August 2014
20 Reads
3 Citations
10.762 Impact Factor

Mortality in patients with multiple sclerosis.

Neurology 2013 Jul;81(2):184-92

Centre of Neuroscience, Division of Experimental Medicine, Department of Medicine, Imperial College, Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e31829a3388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770174PMC
July 2013
13 Reads
20 Citations
8.290 Impact Factor

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

PLoS One 2011 30;6(11):e22444. Epub 2011 Nov 30.

Department of Neurology, University of California San Francisco, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0022444PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227563PMC
April 2012
12 Reads
9 Citations
3.234 Impact Factor

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

J Neurol Neurosurg Psychiatry 2012 Mar 21;83(3):282-7. Epub 2011 Dec 21.

University of California, San Francisco, San Francisco, CA 94143-0114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2011-301178DOI Listing
March 2012
12 Reads
20 Citations
6.810 Impact Factor

Needles: a comparison study.

Med Device Technol 2009 Nov-Dec;20(7):30, 32-4

Bayer HealthCare Pharmaceuticals Inc., Montville, New Jersey 07045, USA.

View Article

Download full-text PDF

Source
February 2010
9 Reads
2 Citations

Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage.

Stroke 2009 Jul 21;40(7):2362-7. Epub 2009 May 21.

Biogen Idec, Wellesley, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.109.547331DOI Listing
July 2009
8 Reads
14 Citations
5.723 Impact Factor

An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration.

Am Heart J 2008 Jul 6;156(1):106-11. Epub 2008 Mar 6.

Bayer HealthCare, Morristown, NJ 07962-1910, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2007.12.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2525513PMC
July 2008
7 Reads
4 Citations
4.463 Impact Factor

Aspirin and clopidogrel resistance: an emerging clinical entity.

Eur Heart J 2006 Jul 2;27(14):1754; author reply 1754-5. Epub 2006 Jun 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehl056DOI Listing
July 2006
3 Reads
15.203 Impact Factor

The dose of aspirin for the prevention of cardiovascular and cerebrovascular events.

Curr Med Res Opin 2006 Jul;22(7):1239-48

Medical Affairs, Bayer HealthCare, Morristown, NJ 07962, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079906x112624DOI Listing
July 2006
2 Reads
2 Citations
2.653 Impact Factor

Comments in response to "low-dose aspirin increases aspirin resistance in patients with coronary artery disease".

Am J Med 2006 Mar;119(3):287; author reply 287-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2005.08.011DOI Listing
March 2006
2 Reads
5.003 Impact Factor

Early impairment in consciousness predicts mortality after hemispheric ischemic stroke.

Crit Care Med 2004 Jan;32(1):241-5

Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.CCM.0000104113.36384.81DOI Listing
January 2004
8 Reads
7 Citations
6.312 Impact Factor

Top co-authors

Douglas S Goodin
Douglas S Goodin

University of California

8
Hans-Peter Hartung
Hans-Peter Hartung

Heinrich-Heine-University

6
Matt Fisher
Matt Fisher

The State University of New Jersey

5
Giancarlo Comi
Giancarlo Comi

San Raffaele Scientific Institute

5
Christoph Pohl
Christoph Pohl

University of Bonn

4
Ludwig Kappos
Ludwig Kappos

University Hospital Basel

4
Rupert Sandbrink
Rupert Sandbrink

University Hospital

4
Massimo Filippi
Massimo Filippi

Vita-Salute San Raffaele University

4